发明公开
- 专利标题: COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
- 专利标题(中): 化合物和组合物作为蛋白激酶抑制剂
-
申请号: EP07717222.9申请日: 2007-02-06
-
公开(公告)号: EP1981870A2公开(公告)日: 2008-10-22
- 发明人: DING, Qiang , REN, Pingda , ZHANG, Qiong , WANG, Xia , SIM, Taebo , ALBAUGH, Pamela A. , GRAY, Nathanael S.
- 申请人: IRM LLC
- 申请人地址: Hurst Holme, 12 Trott Road Hamilton, HM 11 BM
- 专利权人: IRM LLC
- 当前专利权人: IRM LLC
- 当前专利权人地址: Hurst Holme, 12 Trott Road Hamilton, HM 11 BM
- 代理机构: Kiddle, Simon John
- 优先权: US771045P 20060206
- 国际公布: WO2007092531 20070816
- 主分类号: C07D401/04
- IPC分类号: C07D401/04 ; C07D401/14 ; C07D413/14 ; A61K31/4427 ; A61K31/444 ; A61K31/4468
摘要:
The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particulary diseases or disorders that involve abnormal activation of the Abl.Bcr-Abl, Bmx, b-RAF, c-RAFI c-SRC,KDR,CSKlFGFR3,JAK2ILck,Met,PKCalpha,SAPK2alpha)Tie2,TrkB and P70S6K kinases. These compounds have the following structure: (Formula I); in which: R1 is selected from -NR6R7 and -NR6C(O)R8; wherein R6 is selected from hydrogen and C1-6alkyl; R7 is selected from hydrogen, C1-6alkyl. -NR9R10, C6-10aryl-C0-4alkyl, C1-10heteroaryl-C0-4alkyl, C3-12cycloalkyl-C0-4alkyl and C3-8heterocycloalkyl-C0-4alkyl; wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl of R7 can be optionally substituted by 1 to 3 radicals independently selected from C1-6alkyl, C1-6alkoxy, -QNR9R10 and C3-8heterocycloalkyl-C0-4alkyl; wherein Q is selected from a bond and C1-4alkylene; R8 is selected from hydrogen and C1-4alkyl; R9 and R10 are independently selected from hydrogen and C1-6alkyl; R2 is selected from hydrogen and C1-6alkyl; R3 is selected from hydrogen and C1-6alkyl; R4 is selected from hydrogen, halo, C1-6alkyl, C1-6alkoxy, halosubstituted-C1-6alkyl and halosubsb'tuted-C1-6alkoxy; R5 is selected from -C(O)NHR11 and -NHC(O)R11; wherein R11 is selected from C6-10aryl and C1-10heteroaryl; wherein any aryl or heteroaryl of R11 is optionally substituted with 1 to 3 radicals independently selected from halo, C1-6alkyl, C1-6alkoxy, halosubstituted-C1-6alkyl, halosubstituted-C1-6alkoxy, di-C1-4alkyl-amino-C1-6alkoxy, di-C1-4alkyl-amino-C1-4alkyl(C1-4alkyl)amino, C1-10heteroaiyl-C0-4alkyl, C3-8heterocycIoalkyl-C0-4alkyl and C3-8heterocycloalkyl-oxy; wherein any heteroaryl or heterocycloalkyl substituent of R11 is further optionally substituted by 1 to 2 radicals independently selected from C1-6alkyl and hydroxy-C1-6alkyl; X and Y are independently selected from N and CH; and the pharmaceutically acceptable salts, hydrates, solvates and isomers thereof.
信息查询